John Farrell is a science and technology blogger for Forbes online. John was invited to cover proceedings at the 2015 Till & McCulloch Meetings and this is his second report. This blog also appears on Forbes and is reprinted here with permission.
One of the more interesting developments I learned about at the recent Till-McCulloch conference is a novel gene therapy with great promise for HIV patients.
Calimmune, based in Tucson, Arizona, is currently in a Phase I clinical trial to test safety of the procedure, and while the company is holding comment until more data become available, their approach to blocking the HIV virus looks fascinating.
HIV affects over 30 million people worldwide (over 1.2 million in the U.S.), and while there is no cure yet, there are various drug treatments to contain the virus, which attacks the immune system.
Antiretroviral treatments consist of so-called cocktails of chemicals that mainly attack the virus’s ability to replicate in the bloodstream. They have to be taken daily and can have short term and long term side effects.
But what if there were a means of rendering the virus harmless by altering the accessibility of the patient’s own white blood cells? That’s the goal of Calimmune’s treatment, called Cal-1.
HIV attacks the immune system by destroying CD4+ T-lymphocytes, subsets of white blood cells that are crucial to the health of the immune system. A key landing point for the virus is the CCR5 receptor on the outer surface of these white blood cells.
Cal-1 is designed to block the virus by preventing it from binding to CCR5. It achieves this by replacing the CCR5 receptor with a natural variant of the protein found only in the very small percentage of people that are born resistant to HIV.
How it works in broad strokes: The patient’s own blood is drawn and the Cal-1 is introduced into the hematopoietic progenitor/stem cells and the mature CD4+ T lymphocyte populations of white blood cells. The T cells with altered CCR5 will naturally proliferate and outnumber the T cells infected with HIV once they are returned to the patient’s circulation.
It should be noted, Cal-1 is not a cure for HIV, but if it is successful it would allow HIV patients a healthier way to fight the infection than is currently offered with antiretroviral therapies.
As I mentioned, the primary focus of the current initial study is safety. And while the trial officially doesn’t end until September, a company spokesperson told me the company hopes to discuss their data before then.
Definitely a company to keep an eye on in 2016.